Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study seeks to determine the safety and efficacy of shortening the primary and nodal
adjuvant radiation therapy course from 2 Gy x 25 fractions to 3.6 Gy x 10 fractions in merkel
cell carcinoma patients who may or may not be receiving immunotherapy.